Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden

“…IDegLira, a fixed-ratio combination of the basal insulin, insulin degludec (degludec) and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is used as a once-daily subcutaneous injection for the treatment of T2D [5]. Across the IDegLira clinical trial programme, mean end-of-treatment glycated haemoglobin (HbA1c) with IDegLira was \ 53.0 mmol/mol (7.0%), with a mean end-oftrial daily dose of IDegLira ranging from 28 to 45 dose steps [6][7][8][9][10][11][12][13][14]. Overall, IDegLira resulted in improved glycaemic control compared with the use of its components alone [7], with a better weight profile, low rates of hypoglycaemia compared with insulin regimens [10,[12][13][14] and lower levels of gastrointestinal side effects when compared with GLP-1 RA monotherapy [6,8].…”

The History of Insulin Technology: A Brief Review of the Updates in Basal Insulin Therapy Through the Years

“…In the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) V study, significantly fewer episodes of hypoglycemia were reported with the degludec-liraglutide coformulation than with U-100 glargine, whether the coformulation was administered in the morning or in the afternoon and regardless of whether the hypoglycemic threshold was 56 or 70 mg/dL (117). In the DUAL VI study, similarly high proportions of patients attained A1C <7% without hypoglycemia whether the coformulation was titrated once or twice weekly (Table 3) (118).…”